Latest news
Debiopharm and NanoCarrier form Research Collaboration on a new platinum compound using the Medicelle TM technology
Debiopharm S.A. announces the purchase of all outstanding shares of H3 Pharma
Debiopharm S.A. announces marketing approval for a new formulation of Eloxatin® (Oxaliplatin for injection)
H3 Pharma receives approvable letter from FDA for Sanvar® for esophageal variceal bleeding
Debiopharm S.A. and Rowfarma S. de R.L. de C.V. enter into an Exclusive Licensing Agreement in Mexico for two approved…
Debiopharm S.A. and GPC Biotech AG Announce Partnering of Small Molecule MHC Class II Antagonists Program for Autoimune Diseases
Debiopharm S.A. and Tulane Cancer Center nominate Dr T. Curiel and Dr W. Zou, the 2004 Mauvernay Research Excellences Scholars